Ipilimumab/nivolumab/pazopanib

Skin disorder, abnormal liver function tests and lack of therapeutic response in epithelioid sarcoma: case report

    This is a preview of subscription content, access via your institution.

    Reference

    1. Pecora A, et al. Rapid and Complete Response to Combination Anti-CTLA-4 and Anti-PD-1 Checkpoint Inhibitor Therapy in a Patient with Stage IV Refractory End-stage Epithelioid Sarcoma: A Case Report. Journal of Immunotherapy 43: 286-290, No. 9, Nov-Dec 2020. Available from: URL: http://doi.org/10.1097/CJI.0000000000000332

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Ipilimumab/nivolumab/pazopanib. Reactions Weekly 1838, 291 (2021). https://doi.org/10.1007/s40278-021-89608-3

    Download citation